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Aims
To investigate two urinary biomarkers as objective measures of occupational LLMSDs.
Methods
This cross-sectional study involved both working (n 5 146) and case cohorts (n 5 62); the latter were derived from general practitioner referrals or those occupationally re-deployed due to LLMSDs. Urine measurements of the c-telopeptides of collagens I and II and two validated quantitative questionnaires [SF12v2 and the Rheumatoid and Arthritis Outcome Score (RAOS) questionnaires] were the outcome measures.
Results
Urinary collagen II biomarker had largely the same significant discriminant power in distinguishing working from case cohorts, as several item scores within the RAOS questionnaire. Increased perceived pain within the RAOS questionnaire was statistically correlated to higher levels of the collagen II biomarker in all subjects and the combined working cohorts. However, both the pain score and the collagen II biomarker were significant but independent variables in distinguishing cases from non-cases. High levels of current or past sports activity involving the lower limbs were not significant explanatory variables of the collagen II levels. Collagen I biomarker showed no discriminant power between cases and working cohorts, suggesting that increased bone turnover was not a significant feature in the LLMSD cases.
Introduction
Some musculoskeletal disorders (MSDs) affecting the hips, knees and ankles in the lower limbs (LLMSDs) may be related to occupational over-use or abnormal loading of joints. They may also be reflected in pathological and age-related processes of increased destruction of normal cartilage and structural components in bone joints, simulating an osteoarthritic state. However, it is also well recognized that psychological and psychosocial factors may also be important in the presentation of many MSDs and associated symptoms, such as pain [1] [2] [3] . Distinguishing psychosocial and organizational causation from a physically based problem is not necessarily easy. Thus, a validated biomarker sensitive to the early stages of clinically relevant joint disorders, and based on urine samples, could be a cost-effective tool in identifying and controlling the risk of physically driven LLMSDs in high risk occupations. Considerable recent effort has been expended in developing diagnostic tests of 'later life diseases', which include those related to joints and bones. Several urine-based assays have been shown to have some value in the diagnosis and monitoring of osteoarthritis and rheumatoid arthritis. While the clinical value of these tests is not wholly undisputed [4] , their potential for offering objective quantitative evidence of a biologically based problem has been noticed outside clinical medicine [5] . The biomarkers include those related to collagen type I Ó Crown copyright 2011.
metabolism that reflect bone turnover [6] and markers of collagen type II reflecting cartilage turnover [7] , with increased urinary excretion of c-telopeptide of collagen II found in both osteoarthritis and rheumatoid arthritis [8, 9] .
Several questionnaires have been validated and formalized for the clinical investigation of LLMSDs [10, 11] . The Rheumatoid and Arthritis Outcome Score (RAOS) questionnaire includes quantitative scores across separate dimensions of various symptoms and activities of daily living (ADL) [11] . Likewise, generic quality of life questionnaires, such as the SF36 or SF12, have been very widely utilized in public and latterly occupational health [12] and shown themselves useful in case-control or case-general population comparisons. Both types of questionnaires are subjective and cannot distinguish between the involvement of abnormal biological processes and the psychological or organizational factors but nevertheless may help in the characterization of LLMSD cases.
Saxton [13] , albeit in a review of work-related upper limb disorders, proposed a range of biomarkers, including those of collagen metabolism that might be implemented to enable both early warning and more insight into the underlying nature of the disorders. This cross-sectional study investigated if two specific urinary collagens I and II biomarkers, c-telopeptide of collagens I and II reflecting bone and collagen turnover, respectively, could discriminate between normal working subjects and those classified as suffering from an LLMSD. Also the relationships between the urine biomarkers and quantitative scores derived from the RAOS and SF12 questionnaires were investigated.
Methods
Volunteers for the study of the intra-individual variability of the biomarkers were recruited from the Health and Safety Laboratory (HSL). There were no exclusion criteria applied and volunteers were anonymous to the research team. The study questionnaire and two urine collection bottles were supplied to volunteers, requesting on a single day the completion of the questionnaire and collection of 'start of working day' and 'end of working day' spot urine samples. Samples were stored at 240°C until analysis. Analysis was carried out with samples randomized in batches.
The second part of the study applied the same study questionnaire and collected a single random urine sample in a range of volunteers recruited from:
• General practitioner (GP) referrals to hospital specialists because of long-term problems in their lower limbs, these were termed 'clinical cases'. None of these subjects were working at the time of the study.
• Workers who were currently not working or had been re-deployed to another job due to an LLMSD condition, and these subjects were identified through workplace management and occupational health professionals and are termed 'occupational cases'. In the main, those in employment at the time of the study were sedentary workers.
• A range of occupations where significant LLMSD have been reported, e.g. floor layers/carpet fitters and layers [14] [15] [16] , specific construction trades [17] [18] [19] [20] and freight logistics. There were termed the mixed occupational cohort.
• Workers within the construction industry, largely scaffolders, termed the construction cohort.
• HSL workers, as described above.
Inclusion criteria for clinical 'cases' were between 18 and 65 years, reporting significant problems, either pain or functional deficit, in their hips, knees or ankles that were not related to a recent acute trauma. In many cases, a formal diagnosis had not been made, but the majority were thought to have an osteoarthritic condition. Inclusion criteria for 'occupational cases' were of working age and had reported significant problems in their hips, knees or ankles in the last 6 months that had been reflected by a job change or currently being off-sick, unrelated to any recent acute trauma. Re-deployment on the advice of an occupational physician and certified sickness by the GP were identified as due to an LLMSD.
Inclusion criteria for the construction and mixed occupational cohorts were to be currently in employment, with no changes in job or work activities within the last 6 months because of health issues. These subjects were approached through their workplace management. While the large majority of these subjects were current manual workers, a number of them were previously manual workers, now undertaking managerial functions.
Two commercially available enzyme immunoassay kits were used for the measurement in urine of the c-telopeptides of collagen type I and II (Nordic Bioscience Denmark), reflecting bone and cartilage turnover, respectively. The assays were performed according to the kit instructions, using automation to standardize all elements of the assay. The within-day analytical imprecision of both these assays was 7-8%; the between-day imprecision was 12-14%. Results were expressed creatinine corrected.
The questionnaire included three elements, covering joint problems in the lower limbs (RAOS), general quality of life (SF12v2) and a limited amount of personal, occupational and medical data. The RAOS covers five subscales, namely pain, symptoms, ADL, sport/recreation and quality of life, derived from 42 items scored on a five-choice Likert scale. Scores are normalized to 100 points for each subscale, with the accepted format of using higher scores reflecting better outcomes [11] . The SF12v2 questionnaire produces two summary outcome scores for the physical (PCS) and mental component (MCS) normalized to a general population data with a mean of 50 and SD 10; higher scores are associated with better quality of life.
Personal data on sex, age, weight, height and their past and present exposure to vigorous sport/exercise involving the lower limbs were collected. Body mass index (BMI) was estimated using self-reported height and weight. Volunteers' current trade was also collected. Medical history included questions on visits to their GP in the last 12 months for back, arm and lower limb problems, a family history of rheumatic disease and any current medication.
The study proposal was agreed with a National Health Service research ethics committee (REC Reference 06/ Q2703/60) and all participants gave informed consent.
Comparisons between cohorts for continuous variables were undertaken using the non-parametric KruskalWallis test with Dunn's post-test comparison where significance was indicated. Categorical data were analysed using chi-squared tests. Receiver-operating characteristics (ROC) and logistic regression analyses were carried out to look at the discriminatory power of outcome variables.
Results
The demographic information for the five cohorts is shown in Table 1 . Both 'case' cohorts were significantly (P , 0.01) older than the working cohorts but with no significant difference in age between the two case cohorts or between the working cohorts. There were no differences (P . 0.05) between the cohorts in their historical involvement in sports, GP visits concerning lower back, neck or shoulders. However, the proportion of subjects who had visited their GP in the last 12 months for a problem in their hands or arms was significantly higher in the mixed occupation group than the construction group (P , 0.05). The former group also had significantly higher current use (P , 0.05) of non-steroidal anti-inflammatory agents (NSAID) compared to the other working cohorts. All the clinical cases were not working and 55% of the occupational cases were in some form of full-or part-time employment.
Median values in HSL volunteers were significantly higher in morning urine samples compared with afternoon samples for the C-telopeptide collagen I but not for c-telopeptide of collagen II (Wilcoxon tests, P , 0.01 and P . 0.05, respectively). Two subjects gave c-telopeptide collagen II results greater than the quoted reference range. Both were females, pregnant and with a family history of arthritis; the highest value was associated with the third trimester.
The data for both urinary biomarkers suggested a total intra-individual (biological 1analytical) coefficient of variation of 50%, while the within-assay analytical imprecision was 8%. This suggests a significant uncertainty associated with a single urinary measurement.
Results for outcome measures are shown in Table 2 . Both PCS and MCS median scores from the SF12 questionnaire for both case cohorts were lower (P , 0.01) than the working cohorts, with no difference between the two case cohorts. For the MCS, the HSL cohort had lower MCS median outcome (P , 0.05) than the construction cohorts, with no difference between the two other working cohorts. Fifty per cent and 34% of the combined cases had normalized SF12 PCS and MCS scores, respectively, lower or equivalent with the theoretical bottom 2.5th percentile of the general population. For the RAOS questionnaire, the two case cohorts reported worse symptom, pain, ADL and sports/recreation scores (P , 0.001) than the three working cohorts, without statistical difference between the case groups. Interestingly, the mixed occupational cohort showed a worse pain and symptom score (P , 0.05) than the construction cohort but with no statistical differences between working cohorts for sports/recreation or ADL problems. The quality of life (QoL) scores from the RAOS questionnaire were consistent with the SF12 data but with significantly poorer (P , 0.05) values identified in the clinical cases compared to the occupational cases. Both the HSL and the mixed occupational cohorts had significantly worse RAOS QoL scores (P , 0.05) than the construction group.
Clearly, using both the lower limb-specific and more generalized questionnaires, the working cohorts perceived their quality of life as significantly better than the case cohorts, with less symptoms and pain. Figures 1 and 2 show the urinary biomarkers concentrations, creatinine corrected, in the five cohorts. For the c-telopeptide biomarker of collagen I bone degradation, the more sedentary HSL cohort was significantly lower than the two other working cohorts (P , 0.05). No other statistical differences were found.
The medians of the cartilage degradation biomarker were significantly (P , 0.001) higher in the 'case' cohorts than in the three working cohorts, with no significant differences between the three working cohorts or between the two case cohorts. However, when the values from the two pregnant women and the youngest 18 year old were removed, the c-telopeptide of collagen II was higher in the mixed occupation cohort than the sedentary HSL cohort (P , 0.05). The high prevalence in the case cohorts of NSAID medication, where long-term use is associated with a decrease in c-telopeptide of collagen II [21] , may have been operated to reduce the separation between working and case cohorts. A ROC analysis was carried out comparing the combined case cohorts with the combined working cohorts, after excluding those who were pregnant, those who had reported visiting their GP for a lower limb problem in the last 12 months or those who had reported significant pain or problems in their lower limbs. The area under the ROC curve was 0.93 (95% CI 5 0.90-0.97) using a cut-off value of 0.485 mg/mmol creatinine. The sensitivity and specificity were 91 and 84% suggesting good diagnostic discriminatory power. However, this analysis needs to be treated with caution as the case definition is not based on a defined pathology, but rather subjects with long-term absence from work induced change in trade or being referred for expert clinical advice about their lower limb problems.
Correlation analyses between outcome measures and key variables such as age and BMI were carried out for the whole study population (Table 3 ). There were high internal correlations within the RAOS questionnaire and between the two SF12 summary scores. Correlations between RAOS item scores and the SF12 summary scores were lower but still highly significant. No significant association was found between the urine biomarkers suggesting that degradation in these two tissues did not seem coupled. There was a significant negative correlation between age and c-telopeptide collagen I but not the collagen II peptide. The latter biomarker was significantly correlated with BMI (P , 0.01) as with many of the RAOS outcomes.
In contrast, within the combined three working cohorts, the collagen biomarkers were strongly correlated (r 5 0.62; P , 0.001) and the collagen II biomarker was weakly associated with more perceived lower limb pain (P , 0.05).
A backward multiple regression analysis was performed to investigate the relationships between the urine Table 3 . Cross-tabulation of items in the RAOS and SF12 questionnaires and urine biomarkers with Spearman rank correlation coefficients for all the working and case cohorts combined biomarkers and explanatory variables including RAOS questionnaire pain and symptom outcomes, age, BMI, the current and past levels of sports activity, GP visits in the last 12 months for a lower limb or other site-specific problem, reported family history of arthritis and NSAID use in the last week. This analysis was carried out separately for the whole population and the combined working cohorts. For the bone biomarker, only age was included in both final models (P , 0.05). For the c-telopeptide of collagen II cartilage biomarker, there were differences between final models. For the whole population, a biomarker increase was associated with higher BMI (P , 0.05) and more pain by RAOS score (P , 0.001). For the combined working cohorts, the final model suggested that the biomarker was negatively influenced by increasing age (P , 0.05) but positively related to RAOS pain score (P , 0.05).
A logistic model was carried out using case or noncase as the dependent variable and explanatory variables of age, BMI, urine biomarkers, symptom and pain items from the RAOS questionnaire, sports activity and the MCS from the SF12 as a measure of psychological distress. Both urinary c-telopeptide of collagen II (P , 0.01) and RAOS pain score (P , 0.01) were significant but independent discriminatory variables. Increased MCS, possibly reflecting psychological distress, failed to reach significance as an additional influence.
Discussion
Our study found that the cartilage turnover biomarker (c-telopeptide of collagen II) showed significant discrimination between cohorts of workers and cases with lower limb problems derived from clinical referrals and occupational health investigation. The RAOS and SF12 questionnaires indicated significant poorer physical and mental statuses in the cases. In the whole study population, there was a significant correlation between the urinary levels of c-telopeptide of collagen II and perceived levels of symptoms, pain, interference with daily living, quality of life (both physical and mental) and BMI. In logistic regression analysis, c-telopeptide of collagen II and pain score from the RAOS questionnaire appeared as significant independent variables in discriminating between cases and workers.
This study was an initial investigation of the potential value of two objective non-invasive biomarkers reflecting biological stress in joints of the lower limbs and poor occupational outcomes. The study focussed on the ctelopeptides of collagens I and II, a growing body of publications suggests that the c-telopeptide of collagen II reflects abnormal process involved in both rheumatoid and osteoarthritis [22] [23] [24] [25] . Osteoarthritis has been suggested as the biological process underlying the common occupational LLMSDs found in particular trades [16] .
A recent sports medicine study also showed that urinary C-telopeptide of collagen II was increased in training endurance athletes, reflecting stressed joints in the lower limbs in terms of cartilage remodelling or degradation [5] .
The c-telopeptide of collagen I did not discriminate between cases and workers but appears in agreement with previous studies in endurance athletes [5] and construction workers [18] , suggesting adaptive bone remodelling in those undertaking heavy manual work.
Lower limb pain such as knee pain is relatively common in the general population and certain occupations [2, 26, 27, 28] and may have psychological and organizational drivers as well as a pathological basis [1] [2] [3] 29] . This study suggests that the involvement of the latter may be prevalent.
As a cross-sectional study, it cannot be used to investigate the temporal relationship between development of LLMSD and levels of a urine biomarker. The definition of LLMSD is non-standardized between the two case cohorts and in neither was defined on a pathological basis. There was also no attempt to ensure appropriate cross-sectional representation within specific working populations. Thus, caution needs to be applied about over-interpreting the discriminatory power of the collagen II biomarker. However, the clinically validated RAOS questionnaire showed good discrimination between cases and working cohorts, and the SF12 normalized scores in all three working groups reflected their general healthy condition, both questionnaires supporting our classification of case and occupational cohorts. However, this does not exclude some lower limb problems within the working cohorts, as possibly reflected by the RAOS questionnaire and urinary biomarker.
Intra-individual variability of c-telopeptide collagen II excretion suggests that care would be needed in interpreting a single measurement in an individual. Pregnancy and adolescence may also give values that influence a simple adult normal range. These findings reinforce that this biomarker is not specific to an anatomical part of the body but rather to cartilage tissue in any articular joints. Therefore, the use of a questionnaire such as the RAOS would be necessary.
Further studies, and ideally prospective studies, in well-defined cohorts are necessary to further prove the value of urinary c-telopeptide collagen II as a useful marker of biologically driven occupational LLMSDs. Other biomarkers, such as glucosyl-galactosyl-pyridinoline related to synovial degradation, may be useful to give a fuller picture of the biological processes within joints that can impinge on the ability to continue to work effectively.
Besides the further investigation of c-telopeptide collagen II, consideration should also be given to the use of the RAOS and SF12 self-reporting questionnaires in studies of LLMSDs in order to capture quantitative data on perceived poor health outcomes. That both the collagen II urine biomarker and the pain scores from self-reporting questionnaire were significant independent variables in discriminating between LLMSD cases and noncases suggests that they do not serve the same purpose. The urine biomarker only reflects abnormality in the biological process of cartilage turnover; the questionnaire reflects the individual's perception of the extent of their problems, which may also involve additional psychosocial factors.
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Key points
• Occupational musculoskeletal disorders of the lower limbs may involve both biological and psychosocial processes. Measurement of urinary ctelopeptides of collagen II appears as a potentially useful non-invasive biomarker of the biological processes.
• Urinary c-telopeptides are not lower limb specific, so use of a validated questionnaire focused on the lower limbs, such as the Rheumatoid and Arthritis Outcome Score, is necessary to ensure that the urine biomarker is reflecting problems in the lower limb musculoskeletal disorders.
• Urinary c-telopeptides and the Rheumatoid and Arthritis Outcome Score questionnaire pain score were independent predictors of lower limb musculoskeletal disorder in this study, suggesting that they did not give identical information. Consideration should therefore be given to the use of the Rheumatoid and Arthritis Outcome Score and/or SF12 self-reporting questionnaires in occupational studies of lower limb musculoskeletal disorders.
